Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. more
Time Frame | APLT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -23.47% | -2.12% | -3% |
1-Month Return | -90.67% | -3.42% | -0.73% |
3-Month Return | -88.57% | -11.13% | 2.87% |
6-Month Return | -80.22% | -5.74% | 7.17% |
1-Year Return | -70.27% | 3.97% | 25.31% |
3-Year Return | -90.68% | 1.05% | 28.38% |
5-Year Return | -96.44% | 34.37% | 81.89% |
10-Year Return | -90.64% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 10.66M | 9.99M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.74,"profit":true}] |
Cost of Revenue | 23.00K | 380.00K | 415.00K | 441.00K | 353.00K | [{"date":"2019-12-31","value":5.22,"profit":true},{"date":"2020-12-31","value":86.17,"profit":true},{"date":"2021-12-31","value":94.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.05,"profit":true}] |
Gross Profit | (23.00K) | (380.00K) | (415.00K) | (441.00K) | 9.64M | [{"date":"2019-12-31","value":-0.24,"profit":false},{"date":"2020-12-31","value":-3.94,"profit":false},{"date":"2021-12-31","value":-4.3,"profit":false},{"date":"2022-12-31","value":-4.57,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | - | (4.14%) | 96.47% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-4.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 45.58M | 94.47M | 105.62M | 82.95M | 74.53M | [{"date":"2019-12-31","value":43.16,"profit":true},{"date":"2020-12-31","value":89.44,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.54,"profit":true},{"date":"2023-12-31","value":70.56,"profit":true}] |
Operating Income | (45.58M) | (94.47M) | (105.62M) | (82.95M) | (64.53M) | [{"date":"2019-12-31","value":-4558200000,"profit":false},{"date":"2020-12-31","value":-9446600000,"profit":false},{"date":"2021-12-31","value":-10561800000,"profit":false},{"date":"2022-12-31","value":-8295000000,"profit":false},{"date":"2023-12-31","value":-6453500000,"profit":false}] |
Total Non-Operating Income/Expense | 162.00K | 1.06M | 589.00K | 1.13M | (53.86M) | [{"date":"2019-12-31","value":14.37,"profit":true},{"date":"2020-12-31","value":94.41,"profit":true},{"date":"2021-12-31","value":52.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-4778.7,"profit":false}] |
Pre-Tax Income | (45.51M) | (93.96M) | (105.58M) | (82.51M) | (119.76M) | [{"date":"2019-12-31","value":-4551300000,"profit":false},{"date":"2020-12-31","value":-9396100000,"profit":false},{"date":"2021-12-31","value":-10558400000,"profit":false},{"date":"2022-12-31","value":-8250800000,"profit":false},{"date":"2023-12-31","value":-11976300000,"profit":false}] |
Income Taxes | (116.00K) | (939.00K) | (970.00K) | (819.00K) | 185.10K | [{"date":"2019-12-31","value":-62.67,"profit":false},{"date":"2020-12-31","value":-507.28,"profit":false},{"date":"2021-12-31","value":-524.03,"profit":false},{"date":"2022-12-31","value":-442.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (45.40M) | (93.02M) | (104.61M) | (81.69M) | (119.95M) | [{"date":"2019-12-31","value":-4539700000,"profit":false},{"date":"2020-12-31","value":-9302200000,"profit":false},{"date":"2021-12-31","value":-10461400000,"profit":false},{"date":"2022-12-31","value":-8168900000,"profit":false},{"date":"2023-12-31","value":-11994810500,"profit":false}] |
Income From Continuous Operations | (45.51M) | (93.96M) | (105.58M) | (82.51M) | (119.76M) | [{"date":"2019-12-31","value":-4551300000,"profit":false},{"date":"2020-12-31","value":-9396100000,"profit":false},{"date":"2021-12-31","value":-10558400000,"profit":false},{"date":"2022-12-31","value":-8250800000,"profit":false},{"date":"2023-12-31","value":-11976300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (45.40M) | (93.02M) | (104.61M) | (81.69M) | (119.76M) | [{"date":"2019-12-31","value":-4539700000,"profit":false},{"date":"2020-12-31","value":-9302200000,"profit":false},{"date":"2021-12-31","value":-10461400000,"profit":false},{"date":"2022-12-31","value":-8168900000,"profit":false},{"date":"2023-12-31","value":-11976300000,"profit":false}] |
EPS (Diluted) | (4.38) | (4.25) | (4.12) | (2.24) | (1.36) | [{"date":"2019-12-31","value":-438,"profit":false},{"date":"2020-12-31","value":-425,"profit":false},{"date":"2021-12-31","value":-412,"profit":false},{"date":"2022-12-31","value":-224,"profit":false},{"date":"2023-12-31","value":-136,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
APLT | |
---|---|
Cash Ratio | 1.00 |
Current Ratio | 1.06 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
APLT | |
---|---|
ROA (LTM) | -76.01% |
ROE (LTM) | -473.39% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
APLT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.94 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.06 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
APLT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 54.68 |
P/B | 17.38 |
Price/FCF | NM |
EV/R | 62.37 |
EV/Ebitda | NM |
Applied Therapeutics Inc (APLT) share price today is $0.8801
Yes, Indians can buy shares of Applied Therapeutics Inc (APLT) on Vested. To buy Applied Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APLT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Applied Therapeutics Inc (APLT) via the Vested app. You can start investing in Applied Therapeutics Inc (APLT) with a minimum investment of $1.
You can invest in shares of Applied Therapeutics Inc (APLT) via Vested in three simple steps:
The 52-week high price of Applied Therapeutics Inc (APLT) is $10.62. The 52-week low price of Applied Therapeutics Inc (APLT) is $0.84.
The price-to-earnings (P/E) ratio of Applied Therapeutics Inc (APLT) is
The price-to-book (P/B) ratio of Applied Therapeutics Inc (APLT) is 17.38
The dividend yield of Applied Therapeutics Inc (APLT) is 0.00%
The market capitalization of Applied Therapeutics Inc (APLT) is $125.66M
The stock symbol (or ticker) of Applied Therapeutics Inc is APLT